Posted: August 22, 2019 The Global Lung Cancer Coalition (GLCC) and the IASLC have formed a partnership to explore the progress that has been made in lung cancer treatment. Through a […] Read more
Posted: August 14, 2019 Shirish Gadgeel, MBBS, is the Mary Lou Kennedy Research Professor in Thoracic Oncology and a professor in the Division of Hematology/Oncology at the University of Michigan Rogel […] Read more
By Linda Coate, MD, FRCPI, and Hazel O’Sullivan, MB, Bch, BAO, MRCPI Posted: August 14, 2019 Dr. Linda Coate Dr. Hazel O’Sullivan […] Read more
Posted: August 14, 2019 Mark A. Socinski, MD, executive medical director of AdventHealth Cancer Institute, spoke with the IASLC Lung Cancer News about his personal recommendations for TKI-refractory disease, especially for […] Read more
Posted: August 14, 2019 Lorlatinib, a smallmolecule inhibitor of ALK and ROS1, was granted accelerated U.S. Food and Drug Administration approval in November 2018 for patients with ALK-positive metastatic NSCLC whose […] Read more
By Yeol Kim, MD, MPH, PhD, and Choon-Taek Lee, MD, PhD Posted: August 14, 2019 Lung cancer is the leading cause of cancer death worldwide and also in South Korea. Besides […] Read more
By Christian Rolfo, MD, PhD, MBA, Dr.h.c., and Lori Alexander, MTPW, ELS, MWC Posted: August 14, 2019 Targeted therapy has become the standard of care in patients with advanced NSCLC and […] Read more
By Emily F. Collier, MD; Roy S. Herbst, MD, PhD; and Sarah B. Goldberg, MD, MPH Posted: August 14, 2019 Dr. Emily F. Collier Dr. Roy S. Herbst Dr. Sarah B. […] Read more
By Kara Nyberg, PhD Posted: August 14, 2019 The 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) featured hundreds of lung cancer abstracts encompassing the full spectrum of […] Read more
Letter to the Editor: Opening Trials to Patients Living with HIVBy Armelle Lavolé, AP-HP Hôpital Tenon, Paris, FrancePosted: August 14, 2019 In response to the article by Dr. Jarushka Naidoo, […] Read more